MetaCap

Aprea Therapeutics (APRE) vs NuCana (NCNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NuCana is the larger company by market cap ($3.6 million vs $3.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APRE-62.15%NCNA-34.25%
+5%-30%-65%
Oct 7, 20261 yearNov 20, 2026
APRE-62.11%NCNA-31.86%
+3%-31%-65%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APRE versus NCNA key metrics
MetricAPRENCNA
Share price$0.229$0.7495
Market cap$3.25M$3.61M
1-day change-53.56%+4.39%
EPS (TTM)$-0.57$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-12.60M—
52-week high$1.49$4.55
52-week low$0.2036$0.62
Distance from 52-week high-84.63%-83.53%
Analyst consensusnone—
Avg. price target upside+1528.82%—
Average volume388.67K118.13K
Shares outstanding14.19M4.82M
Employees810
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aprea Therapeutics

APRE stock →

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About NuCana

NCNA stock →

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

APRE vs NCNA FAQ

Which is bigger, Aprea Therapeutics or NuCana?

NuCana (NCNA) is larger, with a market capitalization of $3.61M compared with $3.25M for Aprea Therapeutics (APRE).

Are Aprea Therapeutics and NuCana in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons